english Archives - 29 중 6 번째 페이지

GC Genome Debuts on KOSDAQ, Targets Early Cancer Detection Markets in Japan and U.S.

Listing ceremony of GC Genome. [photo=GC Genome] South Korea-based genomics company GC Genome debuted on the KOSDAQ market on June 11, following a successful IPO that attracted strong interest from…

Cheon Okhyeon

2025-06-11

AriBio Signs Alzheimer’s Drug Licensing Deal Worth $600 Million with UAE Pharma Company

[photo=AriBio] AriBio has successfully signed a technology licensing deal worth up to KRW 820 billion (approx. USD 600 million) with a pharmaceutical company based in the Middle East. On June…

Cheon Okhyeon

2025-06-10

K-Bio Showcases Innovation and Pursues One-on-One Partnering at BIO USA

Korean biotech companies are set to make a strong showing at BIO USA 2025, the world’s largest biotech convention, with a focus on technology licensing, global partnerships, and overseas investment.…

Cheon Okhyeon

2025-06-09

PTAB Grants Merck Review of Halozyme Patent Claims, Boosting Alteogen’s Milestone Prospects

The U.S. Patent Trial and Appeal Board (PTAB) has instituted a post-grant review of a key Halozyme patent, following Merck’s petition challenging its validity. The move casts doubt on the…

Cheon Okhyeon

2025-06-04

$GC Biopharma breaks into Malaysia’s plasma fractionation market$

GC Biopharma breaks into Malaysia’s plasma fractionation market

GC Biopharma has won its first-ever government contract in Malaysia for plasma-derived products, marking the first time a Korean company has displaced CSL Behring—the global market leader in plasma therapies—in…

Cheon Okhyeon

2025-06-02

SK Bioscience Expands Vaccine Plant, Secures Facility for 21-Valent Pneumococcal Shot

SK Bioscience has completed the expansion of its Andong L House vaccine plant, securing large-scale production capacity for its 21-valent pneumococcal conjugate vaccine (PCV). The company announced on the 29th…

Cheon Okhyeon

2025-05-29

Celltrion “Remsima SC captures 22% market share in Europe”

Celltrion’s Remsima SC is solidifying its position as a leading autoimmune disease treatment in Europe. On May 28, Celltrion announced that its subcutaneous (SC) formulation of infliximab, “Remsima SC,” had…

Cheon Okhyeon

2025-05-28

Samsung Biologics to Spin Off Biosimilar Unit, Launching a Two-Track Strategy

Samsung Group’s biopharmaceutical business is being reorganized into two separate tracks: CDMO (Contract Development and Manufacturing Organization) and biosimilars. Samsung Biologics plans to conduct a vertical spin-off, separating its subsidiary…

Cheon Okhyeon

2025-05-22

SK Bioscience Prevails Over Pfizer in Patent Dispute

SK Bioscience has secured a decisive victory in a long-standing patent dispute with Pfizer, clearing the path for the company to accelerate its global pneumococcal vaccine business, including exports of…

Cheon Okhyeon

2025-05-21

Weak Earnings, Silent Pipeline: Chong Kun Dang Pharmaceutical Bets on CAR-T and ADC for Comeback

Chong Kun Dang Pharmaceutical Corp., once in the spotlight for a blockbuster licensing deal worth KRW 1.7 trillion ($1.25 billion) at the end of 2023, is now facing a dual…

Cheon Okhyeon

2025-05-20